Sientra (NASDAQ:SIEN) was downgraded by equities researchers at William Blair from an “outperform” rating to a “market perform” rating in a report released on Wednesday, MarketBeat.com reports.
Several other equities analysts also recently issued reports on the company. BidaskClub upgraded Sientra from a “strong sell” rating to a “sell” rating in a research report on Monday, January 7th. Maxim Group upgraded Sientra from a “hold” rating to a “buy” rating in a research report on Wednesday, December 19th. ValuEngine downgraded Sientra from a “buy” rating to a “hold” rating in a research report on Tuesday, February 5th. Finally, Zacks Investment Research upgraded Sientra from a “sell” rating to a “hold” rating in a research report on Friday, November 16th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and eight have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $19.50.
Shares of NASDAQ SIEN opened at $8.34 on Wednesday. The company has a debt-to-equity ratio of 0.36, a current ratio of 2.77 and a quick ratio of 2.34. The company has a market cap of $325.46 million, a PE ratio of -2.57 and a beta of -0.04. Sientra has a 12-month low of $7.74 and a 12-month high of $26.79.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Sientra in the fourth quarter worth approximately $29,000. Great West Life Assurance Co. Can acquired a new stake in Sientra in the fourth quarter worth approximately $64,000. Metropolitan Life Insurance Co. NY lifted its position in Sientra by 356.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 8,191 shares of the medical instruments supplier’s stock worth $104,000 after purchasing an additional 6,397 shares during the period. Dimensional Fund Advisors LP acquired a new stake in Sientra in the fourth quarter worth approximately $135,000. Finally, HRT Financial LLC acquired a new stake in Sientra in the fourth quarter worth approximately $157,000. Hedge funds and other institutional investors own 92.79% of the company’s stock.
Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.
Recommended Story: Investing strategies using the yield curve
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.